QN-302 for Advanced Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a drug called QN-302 in patients with advanced or metastatic solid tumors. The drug is given through an IV on a regular schedule. Researchers want to learn how the drug affects the body and how the body processes it, while also ensuring it is safe for patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study doctor to understand how your current medications might interact with the study drug.
Research Team
Tariq Arshad, MD
Principal Investigator
Qualigen Theraputics, Inc.
Eligibility Criteria
This trial is for patients with advanced or metastatic solid tumors who have seen their cancer progress after all standard treatments, or when no approved therapy exists. They must have a disease that can be measured by RECIST 1.1 criteria.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the study drug QN-302 by intravenous infusion once weekly for 3 weeks every 4-week cycle. Treatment continues as long as it is in the best interest of the patient.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Dose Escalation
Determine maximum tolerated dose (MTD) and establish recommended Phase 2 dose (RP2D) through dose escalation cohorts
Treatment Details
Interventions
- QN-302 (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Qualigen Theraputics, Inc.
Lead Sponsor
Translational Drug Development
Collaborator